---
title: >-
  Real-world (RW) second-line (2L) treatment (tx) patterns and clinical outcomes
  in patients (pts) with HER2-overexpressing biliary tract cancer (BTC).
description: >-
  Explore this publication on real-world evidence: Real-world (RW) second-line
  (2L) treatment (tx) patterns and clinical outcomes in patients (pts) with…
date: '2025-01-01'
category: Publications
tags:
  - COVID-19
  - Poster Presentation
  - Care
  - Approval & Commercialization
  - 'No'
  - Methods/Pharmacoepi
canonical_url: >-
  https://www.headwaterscience.com/resources/publications/di-covid-19/real-world-rw-second-line-2l-treatment-tx-patterns-and/
source: Headwater Science
license: © 2026 Headwater Science. All rights reserved.
slug: real-world-rw-second-line-2l-treatment-tx-patterns-and
id: 7vjMF2ladCFGDzlmJbI44f
contentType: article
---

## Challenge

Real-world second-line treatment patterns and clinical outcomes after first-line therapy failure — specific disease area pending full publication confirmation. Note: flagged for manual verification of disease area and partner institutions.

## Solution

Target RWE researchers analyzed real-world data to characterize second-line treatment patterns, switching rates, and clinical outcomes among patients who failed first-line therapy, providing evidence on treatment sequencing in routine clinical practice.

## Impact

Characterizing second-line treatment patterns and outcomes provides pharma partners developing second-line therapies with competitive context and patient profiling data for positioning new agents.

## Use Cases / Links

Second-line treatment pattern and outcome characterization for pharma partner competitive and gap analysis, Clinical outcomes after first-line failure evidence supporting label and commercial strategy for second-line agents